title: [Efficacy and safety of ambrisentan therapy in Chinese patients with pulmonary hypertension].
abstract: OBJECTIVE
  To explore the efficacy, safety and tolerance of ambrisentan, a high-selective endothelin receptor antagonist, in Chinese patients with pulmonary hypertension (PH).
  
  
  METHODS
  Twenty-eight PH patients (Group 1+Group 4) came from Shanghai East Hospital, Zhongshan Hospital of Fudan University and Fifth People's Hospital of Shanghai were recruited into this open-label, prospective multi-center trial between August 2012 and February 2013. They received 2.5-5.0 mg ambrisentan once daily for 12 weeks. The primary endpoint was the change in exercise capacity showed by six-minute walk distance (6MWD) from baseline to 12 weeks. Secondary endpoints included the changes in World Health Organization (WHO) function class, N-terminal brain natriuretic peptide (NT-proBNP) and liver function test results.
  
  
  RESULTS
  There were 9 males and 19 females with an average age of (35 ± 17) years. The value of 6MWD increased from (372 ± 86) m at baseline to (443 ± 96) m (P = 0.000) after 12 weeks. WHO functional class improved after a 12-week therapy compared to the baseline level (P = 0.000). NT-proBNP decreased from a median of 732 ng/L at baseline to 329 ng/L after 12 weeks (P = 0.046). The baseline liver function test was normal. And liver function test didn't significantly change after a 12-week therapy.
  
  
  CONCLUSIONS
  Ambrisentan therapy is well-tolerated and it improves the exercise capacity and WHO function class in Chinese PH patients.
authors.affiliation: Department of Cardiology, Shanghai East Hospital, Tongji University, Shanghai 200120, China.
authors.forename: Fa-dong
authors.initials: FD
authors.lastname: Chen
authors.forename: Da-xin
authors.initials: DX
authors.lastname: Zhou
authors.forename: Ruo-min
authors.initials: RM
authors.lastname: Di
authors.forename: Yu
authors.initials: Y
authors.lastname: Zou
authors.forename: Wei
authors.initials: W
authors.lastname: Wei
authors.affiliation: Email: lxb70@hotmail.com.
authors.forename: Xue-bo
authors.initials: XB
authors.lastname: Liu
mesh_terms: D000293:Adolescent; D000328:Adult; D000959:Antihypertensive Agents / Q000009:adverse effects / Q000627:therapeutic use; D005260:Female; D006801:Humans; D006976:Hypertension, Pulmonary / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D010666:Phenylpropionates / Q000009:adverse effects / Q000627:therapeutic use; D011446:Prospective Studies; D011724:Pyridazines / Q000009:adverse effects / Q000627:therapeutic use; D016896:Treatment Outcome; D055815:Young Adult
chemical_list: D000959:Antihypertensive Agents; D010666:Phenylpropionates; D011724:Pyridazines; C467894:ambrisentan